Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a
lipid lowering agent (statin) improves sustained virologic response rates in patients who
have previously not responded or relapsed on standard pegylated interferon and ribavirin
therapy.